Loading...
•
Jun 30, 2022
Oncology Institute Q2 2022 Earnings Report
The Oncology Institute's revenue grew driven by focus on pipeline execution and network expansion.
Key Takeaways
The Oncology Institute (TOI) anticipates revenue between $270 to $310 million, representing approximately 33% to 53% growth over 2021 revenue. Gross Profit is expected to be $50 to $60 million and adjusted EBITDA is expected to be between $(20) to $(25) million. TOI anticipates 1.75 million to 2.0 million lives at year end, representing approximately 9% to 25% growth over year-end 2021 lives.
TOI is an early market leader in a large and growing market.
The company has a proven economic model with embedded scalability.
TOI is well capitalized, with a disciplined deployment strategy.
The company's growth enables high-quality, affordable care for more patients.
Oncology Institute
Oncology Institute
Forward Guidance
The Oncology Institute expects revenue between $270 to $310 million, gross profit between $50 to $60 million, and adjusted EBITDA between $(20) to $(25) million for 2022.
Positive Outlook
- Strong year-over-year revenue and lives growth expected
- Continued focus on pipeline execution and network expansion to deliver care under value-based contracts
- Growth in California and new market penetration in Florida and Texas
Challenges Ahead
- Gain sharing contracts and higher mix of FFS-reimbursement is expected to produce lower revenue and gross profit
- TOI’s public company costs are higher than initially projected, mainly due to D&O insurance cost
- Achievement of the anticipated results is subject to risks and uncertainties, including those disclosed in filings with the SEC.
- The outlook does not take into account the impact of any unanticipated developments in the business or changes in the operating environment, nor does it take into account the impact of acquisitions, dispositions or financings during 2022.
- The outlook assumes a largely reopened global market, which would be negatively impacted if closures or other restrictive measures persist or are reimplemented.